Zohaib Haque
Psychiatry · Atlanta, GANPI 1023541935
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $43,650 of the $48,898 with a category attached, or 89.3%. AbbVie accounts for 92.2% of it on its own, with 21 other manufacturers making up the rest. 2025 is the largest year on record at $46,912, more than ten times the $122 reported in 2021. Among psychiatry clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 188 payments — averaging $260.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$45K
- Johnson & Johnson$1K
- Otsuka America Pharmaceutical, Inc.$606
- Axsome Therapeutics, Inc.$368
- Tris Pharma Inc$331
- Neurocrine Biosciences, Inc.$272
- plus $1K from 16 others
What the payments were for
- Speaking & faculty fees$43,65089%
- Travel & lodging$1,2493%
- Food & beverage$3,9248%
- Education$750%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 70 | $45,071 |
| Johnson & Johnson | 22 | $1,098 |
| Otsuka America Pharmaceutical, Inc. | 17 | $606 |
| Axsome Therapeutics, Inc. | 14 | $368 |
| Tris Pharma Inc | 8 | $331 |
| Neurocrine Biosciences, Inc. | 6 | $272 |
| Vanda Pharmaceuticals Inc. | 8 | $262 |
| Alkermes, Inc. | 7 | $161 |
| Teva Pharmaceuticals USA, Inc. | 10 | $152 |
| Intra-sana Laboratories | 1 | $125 |
| Supernus Pharmaceuticals, Inc. | 4 | $94 |
| Acadia Pharmaceuticals Inc | 4 | $70 |
| Lundbeck LLC | 4 | $67 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $58 |
| Neos Therapeutics, LP | 2 | $35 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $29 |
| Merck | 1 | $21 |
| Indivior Inc. | 1 | $18 |
| Noven Therapeutics, LLC | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Tempus AI, Inc | 1 | $14 |
| Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$44,112
- SPRAVATO$529
- REXULTI$364
- Quillichew ER$246
- Quillivant$246
- Dyanavel XR$246
- Reltone 200 Mg$125
- GLYCATE$125
- Reltone 400 Mg$125
- INGREZZA$120
How this compares
$48,898 in reported general payments places this provider in the 95th percentile of 900 psychiatry providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Risperidone | 13 | $1,891 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Atlanta
- David PurselleAtlanta$307K
- Michael BurkeAtlanta$217K
- Bryon EvansAtlanta$211K
- Kerry ResslerAtlanta$196K
- Patricio Riva PosseAtlanta$122K
- Ray HorwitzAtlanta$64K
- Boadie DunlopAtlanta$61K
- Raymond KotwickiAtlanta$44K
- Joseph BergerAtlanta$24K
- Dwight OwensAtlanta$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.